Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can We Foresee Grade and Stage Progression in Mixed Low- and High-Grade Noninvasive Papillary Urothelial Carcinomas?

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026
Same author

Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

Cureus·2026
Same author

Biotinylated Diaryl Isoxazole Derivatives with Enhanced Janus Kinase 1 Inhibitory, Antiproliferative, and Apoptotic Activities in Cancer Cells.

ACS omega·2026
Same author

Hypercontractile phenotype at rest in chronic coronary syndromes predicts impaired functional reserve and increased mortality.

ESC heart failure·2026
Same author

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

Medicina (Kaunas, Lithuania)·2026
Same author

Surgical management of adults with congenital heart disease in Serbia: A pilot model.

International journal of cardiology. Congenital heart disease·2026

Related Experiment Video

Updated: May 23, 2025

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy
05:21

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy

Published on: October 6, 2014

9.6K

AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance.

Seçil Demirkol Canlı1, Güneş Güner2, Aynur Işık3

  • 1Division of Tumor Pathology, Department of Clinical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkiye.

Cancer Medicine
|May 21, 2025
PubMed
Summary

Aldo-keto reductase B1 (AKR1B1) is found in colorectal cancer stroma, particularly in M2 macrophages. Stromal AKR1B1 expression correlates with favorable survival, highlighting the tumor microenvironment

Keywords:
AKR1B1colorectal cancergene expressionprognosisstromatissue microenvironment

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.0K

Related Experiment Videos

Last Updated: May 23, 2025

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy
05:21

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy

Published on: October 6, 2014

9.6K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.0K

Area of Science:

  • Oncology
  • Biochemistry
  • Immunology

Background:

  • Aldo-keto reductase B1 (AKR1B1) is implicated in colorectal cancer (CRC) progression.
  • Previous studies linked AKR1B1 to CRC cell motility, proliferation, and poor prognosis.
  • The role of AKR1B1 in the tumor microenvironment (TME), especially in stromal cells, remains unclear.

Purpose of the Study:

  • To investigate AKR1B1 expression in the CRC TME, focusing on stromal cells.
  • To determine the association between stromal AKR1B1 expression and clinical outcomes in CRC patients.

Main Methods:

  • Analysis of publicly available transcriptomic data from CRC tumors.
  • Single-cell RNA-sequencing to identify cell type-specific AKR1B1 expression.
  • Immunohistochemistry and immunofluorescence in Turkish and Serbian cohorts to assess AKR1B1 and CD163 (M2 macrophage marker) co-localization.

Main Results:

  • AKR1B1 is expressed in both epithelial and stromal components of CRC, with higher levels in the stroma.
  • Single-cell analysis revealed AKR1B1 expression in various immune and stromal cells, notably M2 macrophages.
  • Stromal AKR1B1 expression, particularly in M2 macrophages, correlated with favorable overall survival in Turkish CRC patients.

Conclusions:

  • AKR1B1 expression in the CRC TME, especially within stromal cells like M2 macrophages, influences clinical outcomes.
  • The composition of the TME significantly modulates the impact of AKR1B1 on CRC prognosis.